In patients with multiple risk factors for coronary atherosclerosis (CAD), including type 2 diabetes, interleukin (IL)-1β and other proinflammatory genes and proteins are higher in epicardial adipose tissue (EAT) than subcutaneous adipose tissue (SAT) from the same patients ([@B1]) or EAT from patients without CAD ([@B2]), whereas anti-inflammatory IL-10 is increased ([@B2]) and anti-inflammatory adiponectin is reduced ([@B3]).The relative expression of pro- and anti-inflammatory mediators may determine whether EAT contributes in a harmful or protective paracrine manner to CAD ([@B4]), which might be therapeutically relevant ([@B5]).

IL-1β is secreted by classically activated M1 macrophages, whereas anti-inflammatory IL-1 receptor antagonist (IL-1Ra) and IL-10 are secreted by resident M2 or "alternatively activated" macrophages ([@B6]). IL-1Ra inhibits binding of IL-1β to and activation of its target cell receptor ([@B7]). IL-1Ra was identified in human visceral abdominal fat (VAT) and SAT by Juge-Aubry et al. ([@B8]). The balance between IL-1β and IL-1Ra (the IL-1Ra:IL-1β ratio) is considered to determine the severity of the chronic inflammatory disease ([@B7]), of which CAD is an example. Murine IL-1Ra gene knockout ([@B9]) and human IL-1Ra gene association studies ([@B10]) indicate an important role for IL-1Ra in atherosclerosis. To our knowledge, IL1-Ra has not been reported in EAT. The peroxisome proliferator--activated receptor-γ (PPARγ) mediates the anti-inflammatory action of thiazolidinediones in macrophages ([@B6]).

Our objectives were to determine inflammatory gene expression in EAT contiguous with CAD in patients with metabolic syndrome (MS) and type 2 diabetes and changes associated with pioglitazone therapy.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Control, MS, type 2 diabetic, and pioglitazone-treated type 2 diabetic patients' age, sex, and anthropometric features; metabolic characteristics; drug therapy; study exclusion criteria; fat sample acquisition; mRNA isolation and quantification by RT-PCR; and statistical methods were previously described by us ([@B11],[@B12]). In the current study, additional control subjects (12 vs. 6) were included; insulin resistance was estimated by homeostasis model assessment--insulin resistance (HOMA-IR) ([@B13]) in control subjects and MS patients. At the time of open heart surgery, seven type 2 diabetic patients had been treated with an average dose of 25 mg/day pioglitazone (range 15--45) for an average of 24 months (range 4--60), based on patient recalls of duration of therapy. Gensini scores of angiographic epicardial coronary atherosclerosis ([@B14]) were measured and were significantly lower in control subjects (mean 1.6, range 0--10) than in MS subjects (mean 29.7, range 6--62), type 2 diabetic patients (mean 38.0, range 10--100), and type 2 diabetic patients receiving pioglitazone (mean 30.9, range 17--80). The local institutional review board approved the study, and all patients involved gave their informed consent.

RESULTS {#s6}
=======

[Figure 1*B* and *C*](#F1){ref-type="fig"} show that IL-1Ra and IL-10 mRNAs, respectively, were significantly higher in EAT from MS and type 2 diabetic than control patients, whereas PPARγ was similar ([Fig. 1*D*](#F1){ref-type="fig"}). In anterior thoracic (sternal) SAT, only PPARγ mRNA was lower in MS and type 2 diabetes. There was a trend for higher IL1-β in EAT that was not statistically significant ([Fig. 1*A*](#F1){ref-type="fig"}). However, IL-1β mRNA was significantly greater in EAT than in SAT when measured within patient groups. Thus, for control subjects, mean IL-1β ΔCp was −3.14 for EAT versus −4.73 for SAT (*P* = 0.003); for MS patients, mean IL-1β ΔCp was −3.44 for EAT versus −4.96 for SAT (*P* = 0.007), and, for type 2 diabetic patients, mean IL-1β ΔCp was −3.93 for EAT versus −5.90 for SAT (*P* = 0.02). Pioglitazone therapy in type 2 diabetic patients was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 mRNA in EAT ([Fig. 1*A*--*C*](#F1){ref-type="fig"}) as well as less IL-10 mRNA ([Fig. 1*C*](#F1){ref-type="fig"}) and greater PPARγ ([Fig. 1*D*](#F1){ref-type="fig"}) in SAT.

![IL-1β (*A*), IL-1Ra (*B*), IL-10 (*C*), and PPARγ (*D*) gene expression in epicardial and sternal subcutaneous fat (SAT) from controls (CON), MS, type 2 diabetic (DM), and type 2 diabetic patients treated with pioglitazone (DM + Pio). The data were normalized by the use of cyclophilin as the recovery standard in each run and shown as the means ± SEM of the ΔCp from cyclophilin, with the sign of the ΔCp values reversed so that the greater the number, the more mRNA. The mean ΔCp values for IL1-β, IL-1Ra, and IL-10 mRNAs assayed in EAT were corrected for the lower recovery of cyclophilin in the MS (0.87 units) and type 2 diabetic (0.81 units) groups. No correction was necessary for SAT, since cyclophilin Cp values in this depot were the same in all groups. Likewise, the cyclophilin Cp values in type 2 diabetic patients without and treated with pioglitazone were not significantly different, being 27.20 ± 0.39 and 27.45 ± 0.40 in SAT and 25.81 ± 0.28 and 25.96 ± 0.34 in EAT, respectively; therefore, no correction factor was necessary. Numbers of patients are shown in brackets. The % changes shown in the figures were derived from the ratios and significant differences in the MS or type 2 diabetic patients compared with control subjects as well as type 2 diabetic patients compared with type 2 diabetic patients treated with pioglitazone and are indicated as follows: \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.005. There were no significant differences in expression of the four genes in EAT and SAT between MS and type 2 diabetic patients.](730fig1){#F1}

IL-1Ra and IL-10 mRNAs in EAT from MS and type 2 diabetes that were significantly different from control subjects ([Fig. 1](#F1){ref-type="fig"}) were tested in multiple factor covariate analyses for effects of age, weight, BMI, waist, fasting blood glucose, A1C, HOMA-IR, ACE inhibitors, angiotensin receptor blockers, statins, aspirin, and metformin. None of these variables had a significant impact on the effects arising from MS and type 2 diabetic patients versus control subjects, since these differences also persisted after multiple covariate analysis.

CONCLUSIONS {#s7}
===========

In patients with MS and type 2 diabetes with severe CAD, increased IL-1Ra and IL-10 mRNAs and an upward IL-1β trend were observed in EAT, whereas the three mRNA levels were similar in SAT, highlighting depot-specific gene expression differences and confirming higher IL-10 ([@B2]) in EAT contiguous with CAD.

Macrophages are densely concentrated in EAT around lipid-filled coronary atherosclerotic plaques ([@B5]). Although M1 and M2 macrophages have not been studied in EAT, our data suggested that increases in IL-1Ra and IL-10 expression in EAT might represent a protective mechanism mediated by M2 macrophages in response to activated M1 macrophages recruited possibly by "inside-to-outside" coronary signaling ([@B1]). The expression of IL-1β was not significantly enhanced in EAT, although there was an upward trend. However, IL-1β expression was greater in EAT compared with SAT within MS, type 2 diabetic, and control patient groups, suggesting the possibility that the lack of difference in IL-1β expression in EAT between MS patients, type 2 diabetic patients, and control subjects may have been due to masking by its higher expression in control subjects.

Treatment with pioglitazone in type 2 diabetic patients was associated with reductions in expression of IL-1β, IL-1Ra, and IL-10 in EAT and with only IL-10 in SAT. In this context, rosiglitazone has been shown to directly inhibit phorbol myristate acetate--activated but not basal IL-1Ra release from human SAT explants in vitro ([@B8]). Because pioglitazone suppresses macrophage-mediated adipose tissue inflammation and IL-1β ([@B6]), it can be hypothesized that during pioglitazone therapy, reduced IL1-Ra expression in EAT might have been an indirect consequence of reduced expression of IL-1β in EAT. Pioglitazone was also associated with a selective increase in PPAR-γ mRNA in SAT but not EAT. In as much as EAT is visceral fat originating embryologically from VAT ([@B4]), this finding was consistent with the report of greater pioglitazone-mediated upregulation of PPARγ transcripts in cultured human abdominal SAT preadipocytes than omental preadipocytes in vitro ([@B15]).

In conclusion, augmentation of anti-inflammatory IL-1Ra and IL-10 gene expression in EAT suggested a potentially beneficial role for these adipokines in a proinflammatory milieu contiguous with CAD. Treatment with pioglitazone in type 2 diabetic patients with CAD was associated with a reduction of proinflammatory and anti-inflammatory genes in EAT and a selective increase in PPARγ in SAT.
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